MetaCap

Dogwood Therapeutics (DWTX) vs Talphera (TLPH)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Talphera (TLPH) has outperformed Dogwood Therapeutics (DWTX) over the past year, losing 41.4% versus a loss of 83.7%. Over five years, TLPH leads with a -94.0% price change compared with -99.2% for DWTX. Talphera is the larger company by market cap ($40.8 million vs $39.6 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

DWTX-83.68%TLPH-41.40%
+14%-37%-88%
Nov 21, 20251 yearNov 20, 2026
DWTX-99.25%TLPH-94.55%
+67%-20%-107%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

DWTX versus TLPH key metrics
MetricDWTXTLPH
Share price$1.04$0.7852
Market cap$39.57M$40.80M
1-day change-2.36%+6.25%
YTD return-75.12%-31.12%
1-year return-83.68%-41.40%
5-year return-99.16%-93.96%
P/E ratio (TTM)0.10—
EPS (TTM)$10.26$-0.21
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$28.00K
Net income (latest FY)$-34.26M$-14.29M
Operating margin—-48157.14%
Net margin—-51035.71%
52-week high$7.04$1.57
52-week low$0.901$0.69
Distance from 52-week high-85.31%-49.99%
Analyst consensusnonenone
Avg. price target upside+1252.66%+298.62%
Average volume89.88K144.13K
Shares outstanding38.23M51.96M
Employees812
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • TLPH has outperformed DWTX by 42.3 percentage points over the past year.

About Dogwood Therapeutics

DWTX stock →

Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders. Its lead product candidates include IMC-1, a combination of famciclovir and celecoxib that has completed Phase 2b clinical trial to treat fibromyalgia; Halneuron, which is in Phase 2b clinical trial for the treatment of chemotherapy-induced neuropathic pain and cancer pain, as well as pre-clinical trial for acute surgical pain; and IMC-2, a combination of valacyclovir and celecoxib intended to synergistically suppress herpesvirus activation; and Serpin Peptide 16 that is in early Phase 1 development to reduce neuropathy secondary to treat chemotherapeutic agents that are neurotoxic.

Health Care · Biotechnology: Pharmaceutical Preparations · 8 employees

About Talphera

TLPH stock →

Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate, Niyad, is a lyophilized formulation of nafamostat that acts as a regional anticoagulant for infusion into the extracorporeal circuit.

Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees

DWTX vs TLPH FAQ

Which is bigger, Dogwood Therapeutics or Talphera?

Talphera (TLPH) is larger, with a market capitalization of $40.80M compared with $39.57M for Dogwood Therapeutics (DWTX).

Which stock has performed better over the past year, DWTX or TLPH?

TLPH returned -41.40% over the past 12 months, compared with -83.68% for DWTX (price return, excluding dividends). Past performance does not predict future results.

Are Dogwood Therapeutics and Talphera in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons